Background & Rationale
Understanding how viruses hijack host-cell functions often hinges on decoding direct RNA–RNA interactions between viral genomes/transcripts and host RNAs. These interactions can modulate host mRNA stability and viral replication. Traditional approaches like CLIP-seq or co-immunoprecipitation cannot capture RNA–RNA contacts in situ or at scale. This paper introduces a RIC-seq–based protocol tailored to map high-confidence, native virus–host RNA interactions in infected cells.
Core Analytical Dimensions and Technical Findings
- In situ crosslinking of infected cells with formaldehyde preserves native RNA–RNA proximity before any cell lysis.
- pCp-biotin labeling and in situ RNA ligation on permeabilized cells enable biotin-tagged RNA fragments to be covalently linked based on spatial adjacency.
- Chimeric RNA enrichment and strand-specific library construction ensures accurate identification of both viral and host RNA fragments in a single sequencing read.
- Sequencing and analysis deliver transcriptome-wide maps of virus–host RNA interactions, applicable across RNA viruses—even potentially DNA-virus transcripts.
Interpretation and Industry Relevance
- Holistic virus–host interaction profiling: RIC-seq reveals physical associations between viral and host RNAs—knowledge crucial for understanding viral lifecycle and pathogenesis.
- Functional insight into viral manipulation of host stability: For example, SARS-CoV-2 RNA was found to form >2000 duplexes with host 3′-UTRs, stabilizing host transcripts via YBX3 recruitment in A549 cells.
- Broad applicability across virus types: The protocol works for diverse RNA viruses and may extend to transcripts from DNA viruses, offering a versatile tool for infectious disease research.
Strategic Takeaway
- Expand virology services: Offering RIC-seq for virus–host interaction mapping signals a move beyond conventional transcriptomics or protein-centric assays.
- Build partnerships with antiviral R&D: This method supports early drug discovery by revealing direct RNA targets for therapeutic intervention.
- Diversify assay portfolio: RIC-seq complements other modular sequencing solutions (e.g., RNA-seq, CLIP-seq), enhancing CRO/CDMO competitiveness.
- Capture high-demand workflows: Services grounded in RIC-seq align with urgent pathogen-response needs, making them attractive to clients in biodefense and infectious disease.